CapsoVision Files S-1/A for IPO, Eyes Public Market Debut
Ticker: CV · Form: S-1/A · Filed: Jun 27, 2025 · CIK: 1378325
| Field | Detail |
|---|---|
| Company | Capsovision, Inc (CV) |
| Form Type | S-1/A |
| Filed Date | Jun 27, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: IPO, S-1/A, Electromedical Devices, Emerging Growth Company, Medical Technology, SEC Filing, Capital Raise
TL;DR
**CapsoVision's S-1/A signals an imminent IPO, making it a speculative buy for growth-focused investors in the medical tech space.**
AI Summary
CapsoVision, Inc. filed an S-1/A on June 26, 2025, for its initial public offering, indicating its intent to sell securities to the public as soon as practicable. The company, operating in the electromedical and electrotherapeutic apparatus sector, is headquartered in Saratoga, CA, and is classified as a non-accelerated filer and an emerging growth company. While specific revenue and net income figures are not detailed in this excerpt, the filing signifies a critical step towards public trading, aiming to raise capital for its operations. Key business changes include the formal registration process for public offering under the Securities Act of 1933, with Registration No. 333-287148. Risks associated with this stage typically involve market acceptance of its medical devices and intense competition within the medical technology industry. The strategic outlook is focused on expanding its market presence and product development, leveraging the capital raised from the IPO.
Why It Matters
This S-1/A filing is a crucial step for CapsoVision, Inc. as it moves closer to becoming a publicly traded company, offering investors a new opportunity in the electromedical device sector. For employees, it could mean increased visibility, potential stock options, and growth opportunities as the company expands. Customers might benefit from accelerated product development and broader availability of CapsoVision's medical apparatus. In the broader market, this IPO will intensify competition with established players like Medtronic and Olympus in the diagnostic imaging and therapeutic device space, potentially driving innovation and pricing pressures.
Risk Assessment
Risk Level: medium — CapsoVision is classified as a non-accelerated filer and an emerging growth company, which typically indicates a higher risk profile due to less stringent reporting requirements and a shorter operating history compared to larger, more established companies. The filing itself, an S-1/A, is an amendment to an initial S-1, suggesting ongoing adjustments to its public offering strategy, which can introduce uncertainty.
Analyst Insight
Investors should closely monitor CapsoVision's subsequent filings for pricing details and a clearer picture of its financials before committing capital. Given its 'emerging growth company' status, this is a higher-risk, higher-reward opportunity best suited for investors with a strong appetite for growth in the medical device sector.
Executive Compensation
| Name | Title | Total Compensation |
|---|---|---|
| Kang-Huai (Johnny) Wang | President and Chief Executive Officer |
Key Numbers
- 333-287148 — Registration No. (SEC registration number for the S-1 filing)
- 2025-06-26 — Filing Date (Date S-1/A was filed with the SEC)
- 1933 — Securities Act Year (Act under which the securities are being registered)
- 3845 — SIC Code (Standard Industrial Classification for Electromedical & Electrotherapeutic Apparatus)
- 20-3369494 — IRS EIN (Employer Identification Number for CapsoVision, Inc.)
Key Players & Entities
- CapsoVision, Inc. (company) — Registrant for S-1/A filing
- Kang-Huai (Johnny) Wang (person) — President and Chief Executive Officer of CapsoVision, Inc.
- Portia Ku, Esq. (person) — Counsel at O'Melveny & Myers LLP
- Kurt Berney, Esq. (person) — Counsel at O'Melveny & Myers LLP
- Richard I. Anslow (person) — Counsel at Ellenoff Grossman & Schole LLP
- Jonathan Deblinger (person) — Counsel at Ellenoff Grossman & Schole LLP
- Joseph A. Smith (person) — Counsel at Ellenoff Grossman & Schole LLP
- SEC (regulator) — Securities and Exchange Commission
- O'Melveny & Myers LLP (company) — Legal counsel for the registrant
- Ellenoff Grossman & Schole LLP (company) — Legal counsel for the registrant
FAQ
What is CapsoVision, Inc.'s primary business?
CapsoVision, Inc. operates in the electromedical and electrotherapeutic apparatus industry, as indicated by its SIC Code 3845. This means they develop and manufacture medical devices used for diagnosis and therapy.
When was CapsoVision, Inc.'s S-1/A filed with the SEC?
CapsoVision, Inc.'s Amendment No. 3 to Form S-1 (S-1/A) was filed with the Securities and Exchange Commission on June 26, 2025, under Registration No. 333-287148.
Who is the CEO of CapsoVision, Inc.?
The President and Chief Executive Officer of CapsoVision, Inc. is Kang-Huai (Johnny) Wang, whose contact information is listed at the company's principal executive offices.
What is CapsoVision, Inc.'s status regarding SEC filing requirements?
CapsoVision, Inc. is classified as a non-accelerated filer and an emerging growth company, which impacts its reporting obligations and compliance with certain SEC rules.
Where are CapsoVision, Inc.'s principal executive offices located?
CapsoVision, Inc.'s principal executive offices are located at 18805 Cox Avenue, Suite 250, Saratoga, CA 95070, with a business phone number of +1-408-624-1488.
What does the S-1/A filing mean for CapsoVision, Inc.'s future plans?
The S-1/A filing indicates CapsoVision, Inc. is moving forward with its initial public offering (IPO), aiming to sell securities to the public as soon as practicable after the effective date of the registration statement, likely to raise capital for growth.
Who are the legal counsels involved in CapsoVision, Inc.'s S-1/A filing?
Legal counsels involved include Portia Ku, Esq. and Kurt Berney, Esq. from O'Melveny & Myers LLP, and Richard I. Anslow, Jonathan Deblinger, and Joseph A. Smith from Ellenoff Grossman & Schole LLP.
What is the significance of CapsoVision, Inc. being an 'emerging growth company'?
As an 'emerging growth company,' CapsoVision, Inc. benefits from certain scaled-back disclosure requirements and exemptions from various regulatory provisions under the JOBS Act, which can reduce the cost and burden of being a public company.
What is the approximate date for CapsoVision, Inc.'s proposed sale to the public?
The approximate date of commencement of proposed sale to the public for CapsoVision, Inc. is stated as 'As soon as practicable after the effective date of this registration statement.'
What is CapsoVision, Inc.'s state of incorporation?
CapsoVision, Inc. is incorporated in Delaware, as specified in its charter.
Risk Factors
- Intense Competition in Medical Technology [high — market]: The medical technology industry is characterized by rapid technological advancements and intense competition. CapsoVision faces competition from established companies and emerging players, which could impact its market share and profitability.
- Regulatory Approval and Compliance [high — regulatory]: As a medical device company, CapsoVision is subject to stringent regulatory requirements from bodies like the FDA. Obtaining and maintaining approvals for its devices is critical, and any delays or failures in compliance can significantly impact its business operations and market access.
- Dependence on Key Personnel [medium — operational]: The success of CapsoVision may depend on the continued service of its key management personnel, including Kang-Huai (Johnny) Wang. The loss of such individuals could disrupt operations and strategic initiatives.
- Capital Requirements for Growth [high — financial]: The company's growth strategy, including product development and market expansion, will likely require significant capital. Failure to secure adequate funding through this IPO or other means could hinder its ability to execute its plans.
Industry Context
CapsoVision operates within the electromedical and electrotherapeutic apparatus sector, a segment of the broader medical technology industry. This industry is characterized by rapid innovation, significant R&D investment, and a highly competitive landscape. Companies in this space often face lengthy regulatory approval processes and must navigate complex reimbursement environments.
Regulatory Implications
As a medical device company, CapsoVision is subject to rigorous oversight by regulatory bodies such as the FDA. The S-1/A filing signifies the company's intent to comply with the Securities Act of 1933, requiring comprehensive disclosure. Future operations will necessitate ongoing adherence to both medical device regulations and securities laws.
What Investors Should Do
- Review the full S-1/A filing for detailed financial statements and risk disclosures.
- Assess the competitive landscape and CapsoVision's differentiation strategy.
- Monitor future SEC filings for updates on the IPO process and financial performance.
Key Dates
- 2025-06-26: Filing of S-1/A Amendment — Indicates the company's formal step towards an initial public offering, signaling its intent to raise capital and become a publicly traded entity.
Glossary
- S-1/A
- An amendment to a registration statement filed with the SEC, typically used to update or correct information before an initial public offering (IPO). (This is the core document for CapsoVision's IPO, detailing its business, financials, and risks.)
- Emerging Growth Company
- A company with total annual gross revenues of less than $1.235 billion during its most recently completed fiscal year. These companies are eligible for certain regulatory accommodations. (CapsoVision qualifies as an EGC, which may allow for reduced disclosure requirements and other benefits during its IPO process.)
- Non-accelerated filer
- A filer that does not meet the criteria for accelerated or large accelerated filer status, generally indicating a smaller market capitalization and less public float. (This classification suggests CapsoVision is a smaller public company, potentially impacting investor perception and analyst coverage.)
- SIC Code
- Standard Industrial Classification code, a four-digit number used to classify industries and businesses. (The SIC code 3845 confirms CapsoVision operates in the Electromedical & Electrotherapeutic Apparatus sector, providing context for its industry and competitors.)
- Securities Act of 1933
- A federal law that requires companies to disclose meaningful financial and business information to investors before they can sell securities. It also prohibits deceit, misrepresentations, and other fraud in the sale of securities. (CapsoVision is registering its securities under this act, meaning it must comply with its disclosure and anti-fraud provisions.)
Year-Over-Year Comparison
This is the initial S-1/A filing for CapsoVision, Inc.'s IPO. Therefore, there is no prior filing to compare key metrics such as revenue growth, margin changes, or specific risk factors against. The filing represents a significant transition point for the company as it moves towards public market participation.
Filing Details
This Form S-1/A (Form S-1/A) was filed with the SEC on June 27, 2025 by Kang-Huai (Johnny) Wang regarding CapsoVision, Inc (CV).